Klaus Frueh

Professor

Oregon Health & Science University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Year:

2025

Malaria is one of the most prevalent parasitic diseases in the world. In 2023, 263 million malaria cases were estimated worldwide. Two species of Plasmodium, P. falciparum and P. vivax, cause most human malaria. Despite the licensing of two partially protective vaccines for P. falciparum, there is no vaccine capable of providing long-term control or elimination. A major limitation for vaccine development is the lack of validated T cell epitopes for either species that could be targeted by vaccines. P. vivax is the most widespread human malaria parasite and is the major species causing malaria in the Americas and Asia while P. falciparum is more prevalent in Africa1. P. vivax exclusively infects reticulocytes in peripheral blood, which, unlike the mature erythrocytes infected by P. falciparum, still retain RNA and therefore retain host protein translation capabilities. We previously reported that P. vivax-infected reticulocytes express the major human leukocyte antigen class I (HLA-I), which allows parasite sensing by CD8+ T cells and consequent killing of parasite-infected host cells and intracellular parasites. Here we report by immunopeptidomic analysis the first unbiased identification of Plasmodium spp. antigens presented via HLA-I on infected reticulocytes. We identified 453 unique peptides that mapped to 166 different proteins. Most of these antigens were housekeeping proteins that are constitutively expressed at multiple stages of the parasite life cycle. Common peptides were presented in different individuals by the same or distinct HLA-ABC alleles as well as by non-classical HLA-E. Many peptide sequences were highly conserved in P. falciparum and P. vivax. The immunogenicity of the newly identified epitopes was validated in both P. vivax- and P. falciparum-infected patient samples. Furthermore, several of these antigens were immunogenic in the blood and liver of non-human primates following Plasmodium infection and attenuated parasite immunization. Two antigens were also the target of protective CD8+ T cell-mediated immunity in rodents. Thus, these antigens have potential for use in a cross-stage and cross-species malaria vaccine.

Year:

2025

Congenital cytomegalovirus (cCMV) is the leading infectious cause of birth defects worldwide, yet immune determinants of protection to inform maternal vaccine design remain elusive due to the lack of a translational animal model. Here, we characterized the outcome of primary rhesus CMV (RhCMV) infection in pregnant, immunocompetent, CMV-naïve rhesus macaques. RhCMV DNA was detected in amniotic fluid and/or fetal tissues in six of 12 (50% placental transmission) dams following early second trimester gestation RhCMV inoculation. Widespread tissue dissemination dominated by one of two inoculated RhCMV strains was present in one fetus (8.3% cCMV disease). Placental transmission was associated with elevated fetal and maternal plasma TNF-alpha and reduced maternal brain-derived neurotrophic factor and IL-10 levels. CMV exposure during pregnancy had a broad impact on the placenta and fetus even in the absence of congenital infection, as evidenced by ubiquitous maternal-fetal interface infection, and reduced placental efficiency and small-for-gestation age fetuses compared to control pregnancies. This model recapitulates key aspects of human cCMV and provides new insights into the complexity of CMV vertical transmission.

Year:

2025

Human cytomegalovirus (HCMV) encodes four viral Fc-gamma receptors (vFcγRs) that counteract antibody-mediated activation in vitro , but their role in infection and pathogenesis is unknown. To examine the in vivo function of vFcγRs in animal hosts closely related to humans, we identified and characterized vFcγRs encoded by rhesus CMV (RhCMV). We demonstrate that Rh05, Rh152/151 and Rh173 represent the complete set of RhCMV vFcγRs, each displaying functional similarities to their respective HCMV orthologs with respect to antagonizing host FcγR activation in vitro . When RhCMV-naïve rhesus macaques were infected with vFcγR-deleted RhCMV, peak plasma viremia levels and anti-RhCMV antibody responses were comparable to wildtype infections. However, the duration of plasma viremia was significantly shortened in immunocompetent, but not in CD4+ T cell-depleted animals. Since vFcγRs were not required for superinfection, we conclude that vFcγRs delay control by virus-specific adaptive immune responses, particularly antibodies, during primary infection.

Year:

2024

Collaborators (12)

Nicola Ternette

Professor

University of Dundee

UNITED KINGDOM
View details

Adrian Hill

Director, PI

University of Oxford

UNITED KINGDOM
View details

Joshua Granek

Assistant Professor at Duke University

Duke University

UNITED STATES
View details

Daniel Malouli

Assistant Professor

Oregon Health & Science University

UNITED STATES
View details

Persephone Borrow

University of Oxford

UNITED KINGDOM
View details

Julie L. Mitchell

Research Assistant Professor

Oregon Health & Science University

UNITED STATES
View details

David Morrow

Oregon Health & Science University

UNITED STATES
View details

Andrew James McMichael

Emeritus Professor

University of Oxford

UNITED KINGDOM
View details

Caroline Junqueira

Group Leader

Institute for Research in Biomedicine

SWITZERLAND
View details

Sallie R. Permar

Duke University

UNITED STATES
View details

Paulo Bettencourt

University of Oxford

UNITED KINGDOM
View details

Philipp Kolb

Group leader

University Medical Center Freiburg

GERMANY
View details